Posted by Michael Wonder on 19 Feb 2025
Galderma’s Nemluvio (nemolizumab) granted marketing authorisation in the United Kingdom and Switzerland for moderate to severe atopic dermatitis and prurigo nodularis
18 February 2025 - These are the first approvals of nemolizumab from countries within the Access Consortium framework, with regulatory review processes ongoing in the remaining countries – Australia and Singapore.
Galderma today announced that the UK Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorisation of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively.
